Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

Opinion
Video

Experts discuss the impact of manufacturing and treatment timing on patient outcomes for chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL).

Recent Videos
5 experts in this video
5 experts in this video
Related Content